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Summary.-Lymphoid cells stimulated by soluble tumour antigens in an MCA-
induced murine fibrosarcoma system have been identified by subclass and protective
capacity in adoptive syngeneic hosts. Lymph-node or spleen cells taken at weekly
intervals after inoculation of syngeneic chemically induced fibrosarcomas were en-
riched by 3 methods in T, B, and "null" cell subclasses, and assayed for proliferative
kinetics in response to soluble membrane antigens. The stimulated subpopulations
were found to be heterogeneous, their composition varying with time and tumour
burden. Initial proliferative responses after tumour inoculation were limited to the
T-enriched subpopulation. Later during tumour growth, T, B and null cell fractions
were vigorously and equally stimulated by tumour antigen. The ability of the same
T, B or null-cell subpopulations to inhibit tumour growth was measured in adoptive
hosts by a modified Winn assay. Only the T-cell subpopulation responding to tumour
antigen in vitro effectively and consistently retarded tumour growth in vivo. In
contrast to the shared specificities on syngeneic tumours identified by the prolifera-
tive assay, tumour-growth inhibition was limited to the specific tumour borne by
the cell donor.
SOLUBLE TUMOUR ANTIGENS induce in
vitro proliferation of lymphoid cells from
various tumour-bearing hosts (Jehn et al.,
1970; Gutterman et al., 1972; Meltzer et
al., 1972; Mavligit et al., 1973; Vanky et
al., 1974; Smith, 1975; Forbes et al., 1975;
Gainor et al., 1976; Calderwood et al.,
1977). Reactivity to 3-methylcholan-
threne-induced (MCA) fibrosarcoma anti-
gens is identified first in cells taken from
the regional lymph nodes, and is there-
after detected sequentially in peripheral-
blood lymphocytes, spleen, and non-
regional nodes during the course of
tumour growth. Time-course and dose-
response kinetic data of responses to
various syngeneic tumours have sug-
gested that both shared and nonshared
specificities induce multiclonal prolifera-
tion (Forbes et al., 1975).
In the experiments described here,
lymphocyte subpopulations enriched for
T and B subclasses were examined for
responses to solubilized tumour antigens
at intervals throughout the course of
tumour-bearing. Tumour-growth inhi-
bitory activity of each of these enriched
subpopulations was concurrently assessed
in adoptive syngeneic hosts. The data
show that, while proliferation is stimu-
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lated in each subpopulation, only T cells at
their peak of responsiveness in vitro
inhibit tumour growth.
MATERIALS AND METHODS
Mice.-Age-matched 6-12-week-old female
C57BL/6 mice obtained from The Jackson
Laboratory, Bar Harbor, Maine, or reared in
this laboratory from Jackson breeding stock,
were used in all experiments.
Tumours.-Tumours were induced in mice
by injecting 0 5 mg MCA in 0 1 olive oil i.m.
in each thigh. Tumours arose in 12-16 weeks
and are identified by initials followed by a
number. The tumours or tumour antigens
used in these experiments are designated
PCI, PC5, or PC8. For passage, 104 or 105
trypsinized tumour cells judged viable by
trypan-blue dye exclusion, were transplanted
by i.m. inoculation into the distal thigh of
syngeneic mice. In most cases tumours oflow
passage number were used. No tumour was
used that had been passaged more than 16
times.
All tumours were rapidly growing fibro-
sarcomas (LD5o < 100 cells). An inoculum of
105 viable tumour cells killed the host in
about 4 weeks by local invasion. Lymphoid
hyperplasia always resulted from growth of
these tumours. Spleen and lymph-node cell
(LNC) masses had frequently quadrupled in
cell number at the time of death. Whilst
normal spleens contained about 90% lympho-
cytes, late tumour-bearing spleens contained
10-15% large blastoid cells and increased
numbers ofneutrophils.
Soluble tumour antigens.-Tumour antigens
solubilized in 3M KCI were prepared by a
modification ofRiesfeld's procedure (1971) as
previously described (Forbes et al., 1975).
Soluble antigen prepared from a particular
tumour is referred to by the tumour designa-
tion followed by the symbol [S]. In all experi-
ments soluble antigens were prepared from
tumours of the same in vivo passage number
as the tumours the experimental animals
were bearing. Antigens were stored for not
longer than 4 weeks at 4°C. Selected antigens
were tested in rabbits and found to be pyro-
gen-negative. In the text, "homologous"
tumour antigens refers to the soluble prepara-
tion derived from the same tumour the ex-
perimental animals were bearing; "syn-
geneic" antigen refers to antigen prepared
from other MCA-induced tumours raised in
the same strain of mice.
Lymphoid cell preparations.-Spleen or
popliteal, inguinal, paraortic, and axillary
lymph nodes were aseptically removed from
the mice, pooled, minced, and pressed
through sterile 80-mesh stainless-steel screens
using cold RPMI-1640 (GIBCO, Grand
Island, N.Y.) as the suspending medium.
Mesenteric lymph nodes from normal animals
were also used, and in experiments using
"regional" lymph-node cells (LNC), only the
inguinal and paraortic nodes draining the
tumour site were used. Cell clumps were dis-
persedbydrawing thesuspensionsequentially
through 19, 23 and 25g needles. In experi-
mentsusingspleen cells, red blood cells (RBC)
were lysed by resuspension of the first cell
pellet in 0.83% NH4Cl at room temperature.
Cells were then washed x 3 with cold RPMI.
Total cell counts (excluding RBC) were
determined for each cell mass assayed, and
viability was determined by trypan-blue dye
exclusion.
In some experiments macrophages were
removed by resuspending the lymphoid cells
in RPMI supplemented with 5% foetal calf
serum (GIBCO) and passing the suspension
dropwise through a sterile polypropylene
funnel filled with glass wool (Pyrex Wool,
Corning Glass Works, Corning, N.Y.). The
efficacy ofthis procedure was tested by com-
paring carbon-particle phagocytosis of un-
treated spleen cells and cells from the same
spleen passed once through glass wool.
Untreated spleen-cell suspensions contained
10-15% phagocytic cells, whereas glass-wool-
passed suspensions contained 2-3%. Un-
treated spleen-cell suspensions from tumour-
bearing mice taken late in the course of
tumour growth contained <5% phagocytic
cells, which were removed by glass-wool
passage.
In vitro assay for tumour-antigen stimula-
tion.-The culture method was described pre-
viously (Forbes et al., 1975; Adler et al.,
1970a,b). Either 0 5x 106 or 1x 106 pooled
spleen or LNC were cultured in 12 75mm
polypropylene tubes (No. 2063, Falcon
Plastics, Division of B-D Laboratories, Inc.,
Oxnard, CA.) in 0 5 ml complete medium
RPMI supplemented with 5% normal human
serum, 200 u/ml penicillin, 200 ,ug/ml strepto-
mycin, and 50 ,ug/ml Fungizone). Varying
amounts oftumour antigen (or mitogen) were
added to the cultures in 0 1 ml RPMI.
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FIG. 1. Proliferative responses of spleen
cells (SPL) from normal (0) and tumour-
bearing (0) mice to soluble homologous
tumour antigen (PC8[S]), 21 days after the
inoculation of 105 PC8 tumour cells.
(Phytohaemagglutinin-P [PHA] and lipo-
polysaccharide (S. typhimurium) [LPS] were
obtained from DIFCO Laboratories, Detroit,
MI.) For mixed leucocyte cultures (MLC) 106
irradiated allogeneic spleen cells were added
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in041 ml RPMI. Cultures were incubated in a
5%0 Co2 atmosphere for 72 h. Synthesis of
DNA was measured by the incorporation of
tritiated thymidine (3H-dT) during the last
24h.
Each experiment with tumour-bearing and
age-matched normal control cultures in-
cluded multiple levels of antigen, but these
dose-response titrations are not included in
all the tables in this paper. Fig. 1 illustrates a
typical response of normal and tumour-
bearing spleen cells to a homologous tumour
antigen. Data are presented as mean counts
per minute (ct/min) ± s.e. for 4 replicates.
With increasing amounts of antigen, 3H-dT
incorporation increases to a peak response,
and is inhibited at higher concentrations.
Responses in tumour-bearing spleen cells are
detected as early as 1P5 weeks after tumour
inoculation, the magnitude usually increasing
until the death of the animals at about 4
weeks. Spleen cells from normal animals are
not stimulated.
Soluble antigens from most but not all
syngeneic (non-homologous) MCA-induced
tumours also stimulate tumour-bearing spleen
and LNC in vitro, as previously reported
(Forbes et al., 1975; Calderwood, 1977;
Calderwood et al., 1977). Dose-response re-
lationships are identical to those illustrated
PC
201
50 1000510 20
PC 8
151-
10-
5
50 0 510 20 50
HI PC 5 CS] /.LI PC 8 ES] MuI PC [SI
FIG. 2. Proliferative responses of spleen cells from normal ( ) and tumour-bearing (0) mice to
soluble syngenelc tumour antigen. Spleens from 3-7 mice were pooled and assayedt 3 wreeks after the
inoculation oftuimour cells.
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here for homologous antigens. Examples of
in vitro cross-reactions between PC1, PC5,
and PC8 antigens are illustrated in Fig. 2.
These data are from tumours tested in vivo in
experiments to be described. No significant
response is detected to solubilized normal
muscle prepared in the same manner (Calder-
wood, 1977, p. 61).
Note that the background level of 3H-dT
incorporation in tumour-bearing lymphoid
cell populations is higher than that ofnormal
cell populations, a consistent reflection of
the tumour-associated lymphoid hyperplasia
characteristic of these tumours (Konda et al.,
1973). A high degree of correlation had pre-
viously been shown between "spontaneous"
and antigen-induced 3H-dT incorporation in
tumour-bearing cell populations (Forbes et
al., 1975). For brevity, mean spontaneous
incorporation was subtracted from mean
antigen-induced levels, and results are pre-
sented as net ct/min for the peak response
level of each dose-response titration.
Subpopulation enrichment technique8.-
Complement-mediated cell lysis: Rabbit anti-
mouse brain (RAMB) serum was prepared by
the method of Golub (1971), absorbed once
or twice with 1 part washed mouse RBC to
2 parts serum, and used at a final dilution of
1:30. Goat anti-mouse Ig (anti-Ig), gener-
ously provided by Dr Rebecca Blackstock,
was used at a final dilution of 1:15. The same
pool of guinea-pig complement (C') obtained
lyophilized from Microbiological Associates,
Bethesda, M.D., and reconstituted to original
serum volume with PRMI, was used in all
experiments at a final dilution of 1: 30. Two x
108 spleen or LNC wvere incubated for 60 min
at 37°C with the appropriate dilutions of
RAMB or anti-Ig and C' in a final volume of
30 ml RPMI, then washed x 3 to remove
dead cells. Null cells were prepared by
sequential treatment with anti-Ig+C' then
RAMB+C'. Surviving cells were counted and
used.
Control experiments established the effec-
tiveness and specificity of both goat anti-Ig
and RAMB treatments. In standard cyto-
toxicity tests anti-Ig+C', diluted 1:15, con-
sistently killed 30-40% normal spleen cells
and <5% normal thymocytes. Absorbed
RAMB, diluted 1: 30, killed 30-40% normal
spleen cells, 60-70% LNC, and 95-100%
thymocytes. These cytotoxicity values are
consistent with published data. Additive
toxicity experiments demonstrated that
RAMB and the more conventional AKR anti-
Thy 1.1 killed the same set of cells (Calder-
wood, 1977, p. 53).
The functional efficacy of complement-
mediated cell lysis was tested in each experi-
ment by assaying the responses ofthe residual
cell subpopulation to the B- and T-cell mito-
gens, LPS and PHA. Anti-Ig+C' treatment
greatly increased 3H-dT incorporation by
surviving cells in response to PHA; it reduced
to low levels or eliminated responses to LPS.
RAMB+C' treatment eliminated the PHA
response of the surviving cells and increased
that to LPS. The resultant data are included
as examples of the results from each separa-
tion technique used.
Nylon-wool column separation: T-enriched
spleen-cell fractions were eluted from nylon-
wool columns prepared in 12ml disposable
syringe barrels by the method of Julius et al.
(1973). B-enriched fractions were harvested
by rinsing the columns rapidly with warm
medium, and then compressing the nylon
wool with the syringe plunger. Collected cell
fractions were pooled. The efficacy of this
method ofcell separation was assessed in each
individual experiment in terms offunction of
the surviving cells, as above.
Anti-mouse immunoglobulin columns: The
IgG fraction of anti-Ig was coupled to
cyanogen bromide-activated Sephadex G-200,
prepared as columns and used to remove B
cells by the method ofChess et al. (1974). The
purity of T-enriched subpopulations eluted
by this method was tested as above.
Modified Winn assay.-A modification of
the Winn procedure (1961) was used to test
specific anti-tumour activity of lymphoid
tissues or their subpopulations. Lymphocytes
from spleen, lymph nodes, or lymphoid sub-
populations from these organs were mixed in
various ratios with freshly trypsinized washed
tumour-cell suspensions and injected in a
volume of 0 3 ml into one hind footpad of
syngeneic mice which had been sublethally
irradiated with 4 Gy delivered from an
80OCi 137Cs source at a rate of 10 Gy/min
(Model M Gammator, Radiation Machinery
Corporation, Parsippany, N.J.). The dorso-
ventral thicknesses of the footpads were
measured with a Starrett Dial Gauge Micro-
meter (The L.S. Starrett Co., Athol, Mass.).
Results are expressed as mean tumour-
bearing footpad thickness + s.e., or as mean
net difference between normal and tumour-
bearing foot, + s.e.
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FIG. 3. Proliferative responses t
antigen by surviving spleen-cell si
tions preparedl by treatment witt
and C'. Spleens from 6-7 mice we
treated, and assayed 1-4 weeks
inoculation of 104 PC8 cells. Net
anitigen-stimulated ct/min - sp
ct/min. Spontaneous H3-dT inc
of the untreated tumour-beari
cells was 3649, 3004, 3005, and
min at Weeks 1, 2, 3, 4 respectiV4
tional purity of the subpopula
established eaclh week by mitoge
tion. Example: at 4 weeks, ant
ment enhanced the net, PHA r(
tumour-bearing spleen cells frc
to 86,001 ct/min, while redlucing
response from 112,526 to 7631
treatment reduiced the PHA resp(
71,418 to 6018 ct/min, and inc.
LPS response from 112,526 tc
Control (lata from Weeks 1, 2, a
similar. 0 = untreatecl tumo
spleen cells; A = spleen cells ti'e
anti-Ig+C' (T cells); *=sp
treatecl with RAIB + C' (B cells
RESULTS
Identification of turnour-antige
spleen and LNC subpopulation
To determine which cells wi
ing to soluble antigens in vitro,
week 2 tumour-bearing spleen or LNC suspen-
sions were separated into subpopulations
by 3 different methods: complement-
mediated cytolysis, nylon-wool columns
and anti-Ig columns. Each method gave
similar results.
First, spleen cells taken from tumour-
bearing and control animals at weekly
intervals over a 4-week period of tumour
growth were separated into T- and B-
20 50 enriched fractions by C'-mediated lysis.
JuJi PC8rS3 Surviving cells were cultured with homo-
week 4 logous tumour antigen (Fig. 3). By the
week ~ beginning of the 2nd week of tumour
bearing, when the tumour mass was just
palpable, whole-spleen cells responded,
and the T-enriched fraction response was
the greatest at every level of tumour anti-
gen tested. T-depleted fractions were
minimally responsive. At 3 weeks, the
T-cell fraction was still active, but the
B-enriched fraction was most active. By 4
weeks after tumour inoculation, both
20 5o T-cell and B-cell fractions were highly
jiI PC8 ES3 responsive.
Lo PC8[S] Spleen cells from tumour-bearing mice
ubpopula- were also depleted of glass-wool-adherent
n anti-sera cells, further separated into T- and B-
are ooled, enriched fractions, and an additional sub-
t ct/min= population which survived both anti-Ig
ontaneous or RAMB treatment (null cells). (In orporation
ng spleen normal mice this null-cell subpopulation
12,801 ct/ constituted less than 5%0 of spleen cells.
ely. Furi - As tumour growth progressed, however, 6tions was
n stimula- the subpopulation increased, up to 25% of
i-Ig treat- the spleen cells.) Table I demonstrates
em 71,418 that 17 days after inoculation of tumour
the LPS cells the T-enriched subpopulations were
n.RsAB again the most prominent responders. By
reased the 24 days, however, responses to the T-, B-
D 182,543. and null-cell subpopulations were equal.
tur-bearing Lymph-node cells collected during a
'atedl with similar course of tumour bearing were
ileen eells fractionated by the same method. Table II
shows data from a typical experiment in
which regional LNC were assayed 19 days
after tumour inoculation. Regional LNC
9n-responsive responses were maximal at 2-2-5 weeks t5 and, as is shown, the proliferative response
ere respond- was primarily in the T-enriched subpopu-
normal and lation. LNC (regional, and pooled regional
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TABLE I.-Proliferative responses of spleen-cell subpopulations purified by removal of
adherent cells, and then preselected by complement-mediated cytolysis
Peak 3H-dT incorporation in net ct/min/5 x 105
cellst
M A
Spleen-cell subpopulation
selected*
Normal
Untreated
Anti-Ig+C' (T cells)
RAMB+C' (B cells)
Anti-Ig+RAMB +C' (null cells)
PC1-bearing
Untreated
Anti-Ig+C' (T cells)
RAMB +C' (B cells)
Anti-Ig+RAMB +C' (null cells)
PC1[S] added
17.dys 2 day
17 days 24 days
500
2073
1130
3274
21505
22959
12159
8919
Mitogen added
(17-day data only)
PHA LPS
898 47467
734 105405
703 -81
2262 245
22841
21607
27115
20930
9911
23524
6026
4309
23431
7921
82063
20266
40471
2469
53745
-4012
* Spleen cells from 12 normal or 9 tumour-bearing animals were pooled. Adherent cells were removed by
passing the cell suspensions twice through glass wool before treatment with anti-Ig+C', RAMB+C', or
sequential treatments with both antisera, and then tested for proliferative responses to mitogens or to
PCI[S] antigen.
t Net et/min=peak antigen-stimulated ct/min- spontaneous ct/min/5 x 105 cells.
Mitogen responses for surviving normal and tumour-bearing spleen-cell subpopulations did not differ
significantly at 24 days.
TABLE II.-Proliferat
gional lymph-node
preselected by compl(
lysis
Pe
Lymph-node cell
subpopulations
selected* P
Normal
Untreated
Anti-Ig+C' (T cells)
RAMB +C' (B cells)
PC1-bearing
Untreated 4
Anti-Ig+C' (T cells) I
RAMB +C' (B cells)
* LNC from 30 normal
were pooled before treatm
antisera+C'. Regional LN(
paraortic nodes draining
collected 19 days after the
ive responses of re- obtained by passage through anti-Ig
cell subpopulations columns. Spleen-cell responses to tumour
ement-mediated cyto- antigen at 2 weeks were not reduced by
removal of the immunoglobulin-bearing
3ak 3H-dT incorporation cells. The same cell subpopulation re-
in net et/min/106 cells * i tamed responses to PHA and to alloanti-
Antigen or mitogen gens, but lost reactivity to LPS.
added to culture Fractionation by nylon-wool columns
C1[S] PHA LPS gave similar data, as illustrated in Table
IV. By the 2nd week of tumour bearing,
14 69575 8660 when proliferative responses to tumour
3324 8734 39373 antigen had become highly significant,
removal of T cells reduced the responses
t6277 86255 37007 to both the homologous tumour antigen
15430 111031 15973 PC1[S] and to cross-reacting antigen
-67 -1709 89689 PC5[S]. By the 3rd week, both T- and
or tumour-bearing mice B- cell responses were vigorous These lent with the indicated
"I from the inguinal and data support those derived from the
the tumour site were other fractionation techniques, and those
i.m. inoculation of PCI. derived using the other tumours.
and non-regional) did not respond detect-
ably to soluble tumour antigen after about
3 weeks oftumour bearing.
To confirm the early dominance of the
T-cell subpopulations enriched by C'-
mediated lysis, other methods of separa-
tion were used. The data shown in Table
III illustrate the findings in fractions
Correlation between subpopulation response
in vitro, and capacity to inhibit tumour
growth in vivo
It became clear, in the types of experi-
ments described, that tumour-specific
proliferative responses occurred chiefly in
T-cell subpopulations during early tumour
510IMMUNE RESPONSE TO CHEMICALLY INDUCED TUMOURS
TABLE III.-Proliferative responses of spleen cells passed through anti-mouse Ig columns
Spleen-cell
subpopulations*
Normal
Unfractionated
Passed column (T cells)
PC5-bearing
Unfractionated
Passed column (T cells)
Peak 3H-dT incorporation in net ct/min/106 spleen cells
Antigen or mitogen added to culture
11~~~~~~~~~~~~~~~~~~~~~~~~
PC5[S] PHA LPS C57BL/6 CBA
5429 29664 34674 -1250 21924
5670 117189 23240 -964 27884
20083
21245
6142 11046 -1317 11211
21459 2437 - 1162 9526
* Spleen cells of 5 normal or 3 tumour-bearing mice were pooled and passed through anti-Ig columns.
Cells which were not retained by the column were tested for tumour-specific responses and functional
responses to mitogens and irradiated syngeneic (C57BL) or allogeneic [CBA] spleen cells.
TABLE IV.-Proliferative responses of spleen-cell subpopulations passed through nylon-
wool columns
Spleen-cell
subpopulation
selected*
Normal
Unfractionated
Nylon passed (Tcells)
Nylon retained
PCI-bearing
Unfractionated
Nylon passed (T cells)
Nylon retained
Peak 3H-dT incorporation in net ct/min/106 spleen cells
Mitogen added
PC1[S] added PC5[S] added (Wk 3 only)
A r- -
k r
Wk2 Wk3 Wk2 Wk3 PHA LPS
846 -317
1010 926
259 -192
3939
4583
2701t
16900
16200
17069
1691
2441
494
335 71682
2243 72817
226 50499
2451 14524 28621
8590 22959 58000
1940 14393 15680
87927
6400
90552
98238
32597
120743
* Spleen cells from 5 normal or tumour-bearing mice were pooled prior to passage through nylon-wool
columns. Control mitogen responses for Week 2 were similar.
t Significantly below the response ofunfractionated PCI spleen cells (P <0-001).
growth, but were strong also in B-enriched
and null cells after 3-4 weeks of tumour
bearing. It was of interest to determine
whether the in vitro behaviour of such
subpopulations was associated with a
capacity to retard tumour growth in vivo.
Lymphocyte subpopulations were tested
simultaneously for in vitro response to
soluble tumour antigen and for in vivo
capacity to inhibit tumour growth in an
adoptive host.
The results of a representative experi-
ment are shown in Table V. In this ex-
periment spleen cells were taken at a time
after tumour inoculation (2.5 weeks)
when T-, B- and null-cell subpopulations
all responded vigorously in vitro to tumour
antigen. The spleen cells were fractionated
by C'-mediated lysis, and surviving cell
36
subpopulations were tested with homo-
logous antigen. Aliquots of the same sub-
populations, mixed with viable homo-
logous tumour cells at a 2000: 1 ratio, were
inoculated into the right hind footpads of
groups of 5 sublethally irradiated mice.
Footpad measurements 22 days after
inoculation showed that only the T-cell
subpopulations inhibited tumour growth.
At this time, most animals from the T-cell
group were still tumour-free. Unfraction-
ated tumour-bearing spleen cells retarded
tumour growth slightly. Control cells
were ineffective.
Similar experiments demonstrated that
tumour-bearing lymphocytes best re-
tarded tumour growth in adoptive hosts if
taken 1-5-2-5 weeks after tumour inocula-
tion, when the proliferation by the T-
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TABLE V. Comparison of in vitro proliferative responwes to tamour antigen with in vivo
inhibition of tumour growth
Spleen-cell
subpopulation
s;elected*
Norma:el
Untreated
Anti-Ig+C' (T cells)
RAAMB + C' (B cells)
Anti-Ig + RAA.IIB + C' (null cells)
I'C -beatrinig
Untreated
Anti-Ig+C' (T cells)
RAMIB + C' (B cells)
Anti-Igl+ IgRAMIB+C (nutll cells)
Peak 3H-dT incorporationt
Antigen or mitogen a(dde(l
I- [] PHP PC1 s] PHA LPS
987
1918
2180
3419
11156
17387
20017
20996
5924.9
111642
443
8862
18227
38293
16495
15760
16579
4116
:37071
3678
26269
-4056
6975
-2015
W'inn assay (lata
FPS+ P§
4-80+ 0-18
4-34 + 0-26
5-50+0-31
4-05 + 008
2-83 + 0-52
1-98+0-13
4 77 + 0-12
3-58+0-34
NS
NS
NS
0-(1
0-001
NS
NS
* Spleen cells from 10 normal or 10 tumour-bearing animals inoculated 17 (lays earlier wx itli PC were
pooled before treatment with antiscra + C'.
t Net ct/min5 x 105 surviving cells.
I }Footpad swelling=mean dlorsoventral thickness in mm +s.c. of the iiglht, hiind footpad, whielh lhad becti iniocutlatedi 22 (lays earlier witlh a mixture of 5x 102 viable PCI cells mixed 2 x 106 viable selecte(l or normal spleen cells. Donor lymphocytres were collected( after 1 7 (lays bearing PC1. ,Mean normal left, footpad measurement was 1-78 + 0-00 mm, andl lhas not been subtracted.
§ All footpadl measurements are compared wxitlh those of mice receiving thie mixtture of tumourl cells an(l untreate(l niormal spleen cells. NS =no significant (difference.
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Fi(e. 4. -Growth i curv-es of PCI tumour inocuilated togetlher witlh regional LNC of inoimal or PCI- bearing mice. 103 PCI tumour cells were inoculated togethier with 106 T-enriche(d LNC into the right hind footpa(l (FP) of sublethally irradiated mice. Normal or tumour-bearing regional LNC were pooled from groups of 10 mice after 1, 2, or 3 weeks tumour bearing. Enrichment was by complement-mediated cytolysis. Net FP =mean mm difference in footpad thickness between tumour- bearing and normal feet (groups of5 mice). 0=normal LNC + PCI cells; 0 = tumour-bearing regional LNC + PCI cells.
enriched fraction was most evident in the
in vitro assay. For example, Fig. 4 illus-
trates growth curves from experiments in
which PCI tumour cells were mixed with
normal LN T cells or LN T cells collected
from tumour-bearing mice after 1, 2 or 3
weeks. Inhibition of tumour growth by
tumour-bearing LN T cells was evident at
2 weeks of tumour bearing, correlating
closely with the time of greatest in vitro
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reactivity. Similar results were obtained
in experiments using spleen cells after 1, 2
and 3 weeks tumour bearing.
The lymphoid cell: tumour cell ratio
8
a;
+1
2
a-
LL
z
10:1
used in the above experiments was 1000-
2000: 1. Spleen or LNC were found to
exhibit similar anti-tumour activity at
lymphoid-cell:tumour-cell ratios between
WEEKS POST FP INOCULATION
FIG. 5. Growth curves of tumours inoculated together with various ratios ofspleen T cells. The right
hind footpads of sublethally irradiated mice were inoculated with 103 PCI cells and 104, 105, 106,
or 107 T cells (lymphoid: tumour cell ratios of 10-104: 1) from spleens ofnormal orPCI-bearing mice.
T cells were prepared by anti-Ig+C' treatment of spleen cells pooled from 10 mice, and surviving
cells were used. Net FP as in Fig. 4. O =normal spleen T cells+PCI cells;* =tumour-bearing spleen
T cells collected 2 weeks after tumour inoculation, =PCI cells.
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FiG. 6. Growth curves of tumours inoculated together with normal, homologous, or syngeneic (non-
homologoui) regional LNC. The left hind footpads of sublethally irradiated mice were injected with 103 PC8 or PC5 tumour cells and 106 regional LNC from either age-matched normal or tumour-bear-
ing mice. Pooled LNC were collected after 1, 2, and 3 weeks of tumour bearing from groups of
10-15 mice. O=normal LNC+tumour cells; *=PCI-bearing regional LNC+tumour cells; n =PC5-bearing regional LNC + tumour cells; = PC8-bearing regional LNC + tumour cells.
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PC PC 8 2.5 weeks of tumour bearing and inocu-
lated with PCI or PC8. Only homologous
regional LN T cells inhibited tumour
growth. All 3 tumours showed shared or
cross-reactive responses in the in vitro
assay (Fig. 2). In no combination of
syngeneic tumours tested was adoptive
inhibition of tumour growth detectable.
DISCUSSION
2 3 4 1 2 3 4 The experiments reported here affirm
WEEK POST FP INOCULATION that the lymphoid-cell response to soluble
FIG. 7. Growth curves of tumours inocu- tumour antigen in the in vitro proliferation
lated togethier with normal, homologous, assay reflects a heterogeneous population
or syngeneic (non-homologous) regional which changes during the course of tumour
LN T cells. The left hind footpads of sub-
lethally irradiated mice were injected with growth. Early responses are largely T-cell-
103 PCI or PC8 tumour cells and 106 mediated and are detected first in regional
regional LN T cells from either age-matched lymph nodes, later in other lymph nodes
normal or tumour-bearing mice. Pooled
regional LNC were collected 2-5 weeks after and spleen. B-cell proliferation in response
tumour inoculation from groups of 15 to soluble antigen follows shortly in both
mice. T cells were prepared by complement-
mediated cytolysis. 0=normal LN T cells lymph-node and spleen subpopulations.
+ tumour cells; 0= PC 1-bearing regional Null-cell responses are most prominent
LN T cells+ tumour cells; * = PC8 bearing late in the course of tumour bearing.
regional LN T cells + tumour cells. Although all lymphoid cell subpopulations
were responsive to soluble tumour antigen
102:1 and 104:1, when taken 1-3 weeks in vitro, only the T-enriched subpopulation
after tumour inoculation (Fig. 5). Since inhibited tumour growth appreciably in
the response to soluble antigens from adoptive hosts. This anti-tumour activity
syngeneic tumours was shared or cross- was maximal during the peak of T-cell
reactive in the in vitro assay (Forbes et al., activity in vitro, about 2 weeks after
1975; Fig. 2, Table IV), specificity of tumour inoculation. Neither B cells nor
inhibition of tumour growth was also null cells, as defined herein, detectably
examined in the modified Winn assay. retarded tumour growth at any time,
Cross-reactive anti-tumour activity was despite the vigorous antigen-induced pro-
not demonstrated in any combination of liferative responses observed late in
syngeneic tumour examined. Inhibition tumour bearing. Tumour inhibition ap-
was limited to the homologous tumour peared to be correlated with tumour-
when tested at a ratio of 1000:1. For specific transplantation antigen (TSTA)
example, Fig. 6 shows growth curves of activity (as defined by in vivo immuniza-
PC8 and PC5 tumour injected together tion techniques), whereas the in vitro pro-
with regional LNC taken from animals liferation assay identified shared antigens,
bearing either the homologous tumour or even in the T-enriched subpopulations.
syngeneic tumours, after 1, 2 or 3 weeks of The cell separation techniques used here
tumour bearing. Only LNC regional to made possible the isolation of lymphoid
the homologous tumour retarded tumour cell subpopulations at the peak of their
growth, and this activity was maximal at in vitro responsiveness to tumour-asso-
2 weeks, as before. In the experiment ciated antigens. Even though no single
shown in Fig. 7, T cells from normal technique of T- or B-cell purification
lymph nodes or lymph nodes regional to yields subpopulations completely free
PC8 or PCI tumour were collected after from other cell classes or macrophages,
7
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the data from all 3 enrichment techniques
used here were totally congruent. Opera-
tionally, preselection by C'-mediated lysis
provided the most convenient and effective
method of deriving relatively pure sub-
populations, as judged by functional
responses to mitogens.
The importance of T cells to tumour
rejection in other tumour systems is well
known (Kearney et al., 1975; Bernstein et
al., 1976). T-cell inhibition of homologous
tumour growth in adoptive hosts, shown
here for chemically induced sarcomas,
occurs early in tumour bearing, when the
in vitro proliferative responses are chiefly
T-cell mediated. This is consistent with
the proposition that early T-cell prolifera-
tion, as revealed in the in vitro assay,
reflects the generation of a subset of
tumour-specific T cells directed toward
TSTA, as well as subsets which are cross-
reactive with, or share antigens with,
syngeneic tumours.
Old et al. (1962) found that peritoneal-
exudate cells (PEC) gave singular in-
hibition of tumour growth in the adoptive
host, but LN or spleen cells from the same
hosts had no effect. Their experiments did
not involve purified cell subpopulations,
or explore the early phase of tumour
bearing described here.
We have also found (Smith et al., 1978;
Chauvenet & Smith, 1979) that a high
degree of growth inhibition is afforded by
peritoneal-exudate cells in the adoptive-
transfer technique described here. Such
inhibition was clearly T-cell mediated.
Moreover, long-term-cloned T-cell lines
which show cytotoxicity in vitro and
growth inhibition in vivo for homologous
tumour can be derived from the same PEC
populations (Smith et al., 1980).
The data reported here, taken with
earlier studies, suggest strongly that
tumour-specific T cells are generated early
by proliferation in response to tumour
presence, and that T-cell-mediated in-
hibition of growth of chemically induced
sarcomas is primarily directed toward an
antigenic system or systems not shared
with other syngeneic tumours. A corollary
of this conclusion is that antigen-respon-
sive T cells not protective in vivo are
generated at the same time, and that these
subsets respond to specificities shared
with syngeneic tumours. These experi-
ments emphasize also that tumour-anti-
gen-associated proliferation stimulated by
chemically induced sarcomas also occurs
in B-enriched subpopulations and a large
subpopulation of null cells, chiefly occur-
ring later in tumour bearing. Neither of
these subpopulations inhibits tumour
growth in an adoptive host.
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